{ "instance": { "icpt-20220630x10q.htm": { "axisCustom": 1, "axisStandard": 22, "contextCount": 243, "dts": { "calculationLink": { "local": [ "icpt-20220630_cal.xml" ] }, "definitionLink": { "local": [ "icpt-20220630_def.xml" ] }, "inline": { "local": [ "icpt-20220630x10q.htm" ] }, "labelLink": { "local": [ "icpt-20220630_lab.xml" ] }, "presentationLink": { "local": [ "icpt-20220630_pre.xml" ] }, "schema": { "local": [ "icpt-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 484, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 20, "http://www.interceptpharma.com/20220630": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 27 }, "keyCustom": 49, "keyStandard": 280, "memberCustom": 13, "memberStandard": 34, "nsprefix": "icpt", "nsuri": "http://www.interceptpharma.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document And Entity Information", "role": "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Basis of Presentation", "role": "http://www.interceptpharma.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Discontinued Operations", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Cash, Cash Equivalents and Investment Debt Securities", "role": "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecurities", "shortName": "Cash, Cash Equivalents and Investment Debt Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fair Value Measurements", "role": "http://www.interceptpharma.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Fixed Assets, Net", "role": "http://www.interceptpharma.com/role/DisclosureFixedAssetsNet", "shortName": "Fixed Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Inventory", "role": "http://www.interceptpharma.com/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Accounts Payable, Accrued Expenses and Other Liabilities", "role": "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilities", "shortName": "Accounts Payable, Accrued Expenses and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Long-Term Debt", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Product Revenue, Net", "role": "http://www.interceptpharma.com/role/DisclosureProductRevenueNet", "shortName": "Product Revenue, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_XFucYK8SSkC3-lIYZBR8IQ", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "icpt:ResearchAndDevelopmentTaxCreditTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Research and Development Tax Credit", "role": "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCredit", "shortName": "Research and Development Tax Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "icpt:ResearchAndDevelopmentTaxCreditTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Stock Compensation", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensation", "shortName": "Stock Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Net Loss Per Share", "role": "http://www.interceptpharma.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Commitments and Contingencies", "role": "http://www.interceptpharma.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Subsequent Events", "role": "http://www.interceptpharma.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Cash, Cash Equivalents and Investment Debt Securities (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesTables", "shortName": "Cash, Cash Equivalents and Investment Debt Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_RwmDlMsqG06vY1WRBI6g-Q", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Fixed Assets, Net (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetTables", "shortName": "Fixed Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Inventory (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Accounts Payable, Accrued Expenses and Other Liabilities (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesTables", "shortName": "Accounts Payable, Accrued Expenses and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Long-Term Debt (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Product Revenue, Net (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureProductRevenueNetTables", "shortName": "Product Revenue, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Stock Compensation (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationTables", "shortName": "Stock Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.interceptpharma.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_5_5_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_-LiXkIIQT0qRJLrj4ds_ag", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Overview of Business (Details)", "role": "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "shortName": "Overview of Business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_sOAnOrefrUenrxcZxKwOKA", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_5_5_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_-LiXkIIQT0qRJLrj4ds_ag", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Discontinued Operations (Narratives) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "shortName": "Discontinued Operations (Narratives) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Discontinued Operations (Assets and Liabilities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "shortName": "Discontinued Operations (Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_Ydfa2815T0688J0EJoTB-Q", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_Afx6uGILE0uTX-HZKiceGA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Discontinued Operations (Results of operations) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "shortName": "Discontinued Operations (Results of operations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_Afx6uGILE0uTX-HZKiceGA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Discontinued Operations (Net cash provided by operating activities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "shortName": "Discontinued Operations (Net cash provided by operating activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_y9tODqCMrkSYf9i60eH7ww", "decimals": "-3", "lang": null, "name": "icpt:DisposalGroupIncludingDiscontinuedOperationAdjustmentOfNonCashActivities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "icpt:CashAndCashEquivalentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Cash, Cash Equivalents and Investment Debt Securities (Cash, Cash Equivalents and Investment Debt Securities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Investment Debt Securities (Cash, Cash Equivalents and Investment Debt Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "icpt:CashAndCashEquivalentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Cash, Cash Equivalents and Investment Debt Securities (Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "shortName": "Cash, Cash Equivalents and Investment Debt Securities (Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_pAZrYDDpskabHJOLNZ_QDQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Cash, Cash Equivalents and Investment Debt Securities (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesNarrativeDetails", "shortName": "Cash, Cash Equivalents and Investment Debt Securities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_pAZrYDDpskabHJOLNZ_QDQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fair Value Measurements (Fair Value, Marketable Securities Measured on Recurring and Nonrecurring Basis) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "shortName": "Fair Value Measurements (Fair Value, Marketable Securities Measured on Recurring and Nonrecurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Fair Value Measurements (Schedule of Available for Sale Securities Debt Maturities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails", "shortName": "Fair Value Measurements (Schedule of Available for Sale Securities Debt Maturities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_uBSTLTcdHk2Dc25ritf4zQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Fair Value Measurements (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Fixed Assets, Net (Fixed Assets Stated at Cost) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails", "shortName": "Fixed Assets, Net (Fixed Assets Stated at Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Inventory (Schedule of Inventory) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails", "shortName": "Inventory (Schedule of Inventory) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Accounts Payable, Accrued Expenses and Other Liabilities (Schedule of Accounts Payable and Accrued Liabilities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable, Accrued Expenses and Other Liabilities (Schedule of Accounts Payable and Accrued Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_XFucYK8SSkC3-lIYZBR8IQ", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_8_20_2021_To_8_20_2021_zZJXdXVP6kK_673i-7N7jg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Long-Term Debt - Narratives (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "shortName": "Long-Term Debt - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_8_20_2021_To_8_20_2021_zZJXdXVP6kK_673i-7N7jg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_EyOKqUKrikObsSdYO97yrg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Long-Term Debt (Schedule of Long-term Debt Instruments and Interest Expense) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "shortName": "Long-Term Debt (Schedule of Long-term Debt Instruments and Interest Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "icpt:ScheduleOfInterestExpensesOnConvertibleNotesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "lang": null, "name": "icpt:ContractualInterestExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_yEqx0R76lEm017Y-Fzv8ng", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Long-Term Debt - Fair value of convertible debt (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "shortName": "Long-Term Debt - Fair value of convertible debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_yEqx0R76lEm017Y-Fzv8ng", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_uBSTLTcdHk2Dc25ritf4zQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Long-Term Debt - Exchange of convertible debt - Narratives (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "shortName": "Long-Term Debt - Exchange of convertible debt - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleThresholdTradingDays", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_D_ybQVDKaA8UKOVgEyQNQ5Dg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Long-Term Debt - Note Indentures (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "shortName": "Long-Term Debt - Note Indentures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleThresholdTradingDays", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_D_ybQVDKaA8UKOVgEyQNQ5Dg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_o5CEiD-Py06-8T0igDVM5Q", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41006 - Disclosure - Long-Term Debt - Initial conversion of convertible debt (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "shortName": "Long-Term Debt - Initial conversion of convertible debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSecuredNotesThreePointFivePercentMember_o5CEiD-Py06-8T0igDVM5Q", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_9_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSeniorNotesThreePointTwoFivePercentMember_ZwPIklQoL0WI-npAhZWgQg", "decimals": "INF", "first": true, "lang": null, "name": "icpt:BaseCappedCallOptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41007 - Disclosure - Long-Term Debt - Capped Call Transactions (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "shortName": "Long-Term Debt - Capped Call Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_9_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_icpt_ConvertibleSeniorNotesThreePointTwoFivePercentMember_ZwPIklQoL0WI-npAhZWgQg", "decimals": "INF", "first": true, "lang": null, "name": "icpt:BaseCappedCallOptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_qeU2lc1ZQEKp5o5DhHuFfA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41008 - Disclosure - Long-Term Debt - Interest Expense (Details)", "role": "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "shortName": "Long-Term Debt - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_qeU2lc1ZQEKp5o5DhHuFfA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oj6kd83jHUu4FkwYGkOHaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Changes in Stockholders' (Deficit)", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oj6kd83jHUu4FkwYGkOHaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Product Revenue, Net (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "shortName": "Product Revenue, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_XFucYK8SSkC3-lIYZBR8IQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Product Revenue, Net (Allowance for credit losses) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureProductRevenueNetAllowanceForCreditLossesDetails", "shortName": "Product Revenue, Net (Allowance for credit losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "icpt:ResearchAndDevelopmentTaxCreditTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_85fIhe_JDEewpH2DbVCHLQ", "decimals": "3", "first": true, "lang": null, "name": "icpt:PercentageOfCreditEligibleFromTaxAuthority", "reportCount": 1, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Research and Development Tax Credit (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails", "shortName": "Research and Development Tax Credit (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "icpt:ResearchAndDevelopmentExpenseDecreaseForeignCurrencyTranslation", "p", "icpt:ResearchAndDevelopmentTaxCreditTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_ZHw2meILK0ivbucH7Nm_Ng", "decimals": "-5", "lang": null, "name": "icpt:ResearchAndDevelopmentExpenseDecreaseForeignCurrencyTranslation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Stock Compensation (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "shortName": "Stock Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_XFucYK8SSkC3-lIYZBR8IQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Stock Compensation (Schedule of Share Based Compensation Stock Options Activities) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails", "shortName": "Stock Compensation (Schedule of Share Based Compensation Stock Options Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QGqbaNDY00a9-6QAiiPxUw", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41303 - Disclosure - Stock Compensation (Schedule of Share Based Compensation Arrangement By Share Based Payment Award Grants in Period Fair Value Assumptions) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails", "shortName": "Stock Compensation (Schedule of Share Based Compensation Arrangement By Share Based Payment Award Grants in Period Fair Value Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QGqbaNDY00a9-6QAiiPxUw", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_hM1sB5XEKkGxJNxAXtld3g", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_icpt_RestrictedAndPerformanceStockUnitsPsusAndAwardsMember_TQ1EotRWjEqznbK3dmwJaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41304 - Disclosure - Stock Compensation (Schedule of Share-based Compensation, Restricted Stock Units and Award Activity) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails", "shortName": "Stock Compensation (Schedule of Share-based Compensation, Restricted Stock Units and Award Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_icpt_RestrictedAndPerformanceStockUnitsPsusAndAwardsMember_TQ1EotRWjEqznbK3dmwJaA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41305 - Disclosure - Stock Compensation (Schedule of Stock Based Compensation Expense) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails", "shortName": "Stock Compensation (Schedule of Stock Based Compensation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Net Loss Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Net Loss Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_wUQrRR0e7UK3l50LQH1B4g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_HHG-zvbHeEy9Vk_0lZhNmg", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_7_1_2022_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YXwQPY7Z-USTt6_1ExtJtg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Subsequent Events (Narrative) (Details)", "role": "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails", "shortName": "Subsequent Events (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "As_Of_7_1_2022_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_icpt_ExU.s.CommercialOperationsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YXwQPY7Z-USTt6_1ExtJtg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00505 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hJFMmqU__kaVlkDg0Ycl_A", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Overview of Business", "role": "http://www.interceptpharma.com/role/DisclosureOverviewOfBusiness", "shortName": "Overview of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "icpt-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_gkUixgdItEKbwNywDP_bdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 54, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.interceptpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "icpt_AccruedContractedServices": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued contracted services.", "label": "Accrued Contracted Services", "terseLabel": "Accrued contracted services" } } }, "localname": "AccruedContractedServices", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_AdditionalCappedCallOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional capped call options outstanding.", "label": "Additional Capped Call Options Outstanding", "terseLabel": "Additional Capped Call Options" } } }, "localname": "AdditionalCappedCallOptionsOutstanding", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_AdditionalCappedCallOptionsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional capped call options terminated.", "label": "Additional Capped Call Options Terminated", "terseLabel": "Additional Capped Call options, terminated" } } }, "localname": "AdditionalCappedCallOptionsTerminated", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_BaseCappedCallOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of base capped call options outstanding.", "label": "Base Capped Call Options Outstanding", "terseLabel": "Base Capped Call options" } } }, "localname": "BaseCappedCallOptionsOutstanding", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_BaseCappedCallOptionsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of base capped call options terminated.", "label": "Base Capped Call Options Terminated", "terseLabel": "Base Capped Call options, terminated" } } }, "localname": "BaseCappedCallOptionsTerminated", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_CappedCallOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of capped call options outstanding.", "label": "Capped Call Options Outstanding", "terseLabel": "Capped Call options" } } }, "localname": "CappedCallOptionsOutstanding", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_CappedCallOptionsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of capped call options terminated.", "label": "Capped Call Options Terminated", "terseLabel": "Options terminated" } } }, "localname": "CappedCallOptionsTerminated", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_CashAndCashEquivalentsAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amortized cost of cash and cash equivalents.", "label": "Cash and Cash Equivalents, Amortized Cost", "verboseLabel": "Cash and Cash Equivalents, Amortized Cost" } } }, "localname": "CashAndCashEquivalentsAmortizedCost", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_CashAndCashEquivalentsAndInvestmentsAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount of cash and cash equivalents and investment in securities amortized cost.", "label": "Cash and Cash Equivalents and Investments, Amortized Cost", "verboseLabel": "Total cash and cash equivalents and investment debt securities, Amortized Cost" } } }, "localname": "CashAndCashEquivalentsAndInvestmentsAmortizedCost", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_CashAndCashEquivalentsAndInvestmentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value disclosure of cash and cash equivalents and investment in securities.", "label": "Cash and Cash Equivalents and Investments, Fair Value Disclosure", "verboseLabel": "Total cash and cash equivalents and investment debt securities, Fair Value" } } }, "localname": "CashAndCashEquivalentsAndInvestmentsFairValueDisclosure", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGains": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount of gross unrealized gains of cash and cash equivalents and investment in securities.", "label": "Cash and Cash Equivalents and Investments, Gross Unrealized Gains", "verboseLabel": "Total cash and cash equivalents and investment debt securities, Gross Unrealized Gains" } } }, "localname": "CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGains", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_CashAndCashEquivalentsAndInvestmentsUnrealizedLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount of unrealized losses of cash and cash equivalents and investment in securities.", "label": "Cash and Cash Equivalents and Investments, Unrealized Losses", "negatedLabel": "Total cash and cash equivalents and investment debt securities, Gross Unrealized Losses" } } }, "localname": "CashAndCashEquivalentsAndInvestmentsUnrealizedLosses", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and money market funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "icpt_ContractualInterestExpense": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetailsAlternate": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual interest expense.", "label": "Contractual Interest Expense", "terseLabel": "Contractual interest expense" } } }, "localname": "ContractualInterestExpense", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "icpt_ConvertibleSecuredNotesThreePointFivePercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to convertible secured notes three point five percent.", "label": "2026 convertible secured notes" } } }, "localname": "ConvertibleSecuredNotesThreePointFivePercentMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "domainItemType" }, "icpt_ConvertibleSeniorNotesThreePointTwoFivePercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes 3.25% [Member].", "label": "2023 Convertible Notes" } } }, "localname": "ConvertibleSeniorNotesThreePointTwoFivePercentMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "icpt_ConvertibleSeniorNotesTwoPercentDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Two Percent Due 2026[Member]", "label": "2026 Convertible Notes" } } }, "localname": "ConvertibleSeniorNotesTwoPercentDue2026Member", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "icpt_ConvertibleSeniorSecuredNotes3.50Due2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Secured Notes Three Point Five Due 2026 [Member].", "label": "2026 Convertible Secured Notes" } } }, "localname": "ConvertibleSeniorSecuredNotes3.50Due2026Member", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "icpt_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument, Convertible Threshold Consecutive Business Days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveBusinessDays", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "durationItemType" }, "icpt_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument, Convertible Threshold Consecutive Trading Day Period" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "durationItemType" }, "icpt_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.", "label": "Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum" } } }, "localname": "DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "percentItemType" }, "icpt_DebtInstrumentDefaultThresholdPercentageOfAggregatePrincipalAmountOfDebtHoldersWhoCanDeclareDueAndPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of aggregate principal amount of debt holders who can declare the notes due and payable in the event of default occurring and continuing.", "label": "Debt Instrument, Default, Threshold Percentage Of Aggregate Principal Amount Of Debt Holders Who Can Declare Due And Payable" } } }, "localname": "DebtInstrumentDefaultThresholdPercentageOfAggregatePrincipalAmountOfDebtHoldersWhoCanDeclareDueAndPayable", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "percentItemType" }, "icpt_DebtInstrumentNumberOfSeriesOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of series of convertible notes.", "label": "Debt Instrument, Number Of Series Of Convertible Notes" } } }, "localname": "DebtInstrumentNumberOfSeriesOfConvertibleNotes", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "integerItemType" }, "icpt_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year through second fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Two Years, Fair Value", "terseLabel": "Due after one year through two years" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationAdjustmentOfNonCashActivities": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 6.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustment of non cash activities attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Adjustment of Non Cash Activities", "terseLabel": "Adjustment of non-cash activities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAdjustmentOfNonCashActivities", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable", "terseLabel": "Additional contingent consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationDecreaseInInventory": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 3.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in inventory attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Decrease in Inventory", "terseLabel": "Decrease in inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDecreaseInInventory", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationDecreaseInPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 4.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in prepaid expenses and other current assets attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Decrease in Prepaid Expenses and Other Current Assets", "terseLabel": "Decrease in prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDecreaseInPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationDecreaseInSecurityDeposits": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 2.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in security deposits attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Decrease in Security Deposits", "terseLabel": "Decrease in security deposits" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDecreaseInSecurityDeposits", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationIncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 1.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Increase (decrease) in accounts payable, accrued expenses and other current liabilities in security deposits attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Increase (Decrease) in Accounts Payable, Accrued Expenses and Other Current Liabilities", "terseLabel": "Increase (decrease) in accounts payable, accrued expenses and other current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationIncreaseInAccountsReceivable": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 5.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in receivable attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Increase in Accounts Receivable", "negatedLabel": "Increase in accounts receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIncreaseInAccountsReceivable", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeNet": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Other (expense) income attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other (Expense) Income, Net", "terseLabel": "Other (expense) income, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeNet", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Research and development attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Research and Development", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationRestructuring": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring income attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Restructuring", "terseLabel": "Restructuring" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuring", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "icpt_DisposalGroupIncludingDiscontinuedOperationSecurityDepositCurrent": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as security deposit attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Security Deposit, Current", "terseLabel": "Security deposits" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationSecurityDepositCurrent", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_EquityIncentivePlanTwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan 2022 [Member]", "label": "Equity Incentive Plan (\"2022 Plan\")" } } }, "localname": "EquityIncentivePlanTwoThousandAndTwentyTwoMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "icpt_ExU.s.CommercialOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Ex-U.S Commercial Operations.", "label": "Ex-U.S. commercial operations", "terseLabel": "Ex-U.S. commercial operations" } } }, "localname": "ExU.s.CommercialOperationsMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "icpt_ExchangeOf2023ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exchange of 2023 convertible notes.", "label": "Exchange of 2023 Convertible Notes" } } }, "localname": "ExchangeOf2023ConvertibleNotesMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "domainItemType" }, "icpt_InvestmentDebtSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Not Available.", "label": "Investment Debt Securities Abstract" } } }, "localname": "InvestmentDebtSecuritiesAbstract", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "icpt_LongTermLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities [Abstract]", "verboseLabel": "Long-term liabilities:" } } }, "localname": "LongTermLiabilitiesAbstract", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "icpt_NetIncreaseDecreaseInAccruedFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net increase (decrease) in accrued fixed assets.", "label": "Net Increase Decrease in Accrued Fixed Assets", "terseLabel": "Net increase in accrued fixed assets" } } }, "localname": "NetIncreaseDecreaseInAccruedFixedAssets", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "icpt_NoncashOperatingLeaseCost": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash operating lease cost.", "label": "Noncash Operating Lease Cost", "terseLabel": "Non-cash operating lease cost" } } }, "localname": "NoncashOperatingLeaseCost", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "icpt_OverviewOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Overview of Business" } } }, "localname": "OverviewOfBusinessAbstract", "nsuri": "http://www.interceptpharma.com/20220630", "xbrltype": "stringItemType" }, "icpt_PaymentOfUnderwritingDiscountsCommissionsAndEstimatedOfferingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow on payment of underwriting discounts, commissions, and estimated offering expenses.", "label": "Payment Of Underwriting Discounts, Commissions, And Estimated Offering Expenses", "verboseLabel": "Cost of debt issued" } } }, "localname": "PaymentOfUnderwritingDiscountsCommissionsAndEstimatedOfferingExpenses", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_PaymentsForRepurchaseOfConvertibleSeniorNotes": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for repurchase of convertible senior notes made during the period.", "label": "Payments for Repurchase of Convertible Senior Notes", "negatedLabel": "Payments for repurchases of convertible senior notes" } } }, "localname": "PaymentsForRepurchaseOfConvertibleSeniorNotes", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "icpt_PaymentsForRepurchaseOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow on payments for repurchase of debt.", "label": "Payments For Repurchase Of Debt", "terseLabel": "Convertible debt repurchased" } } }, "localname": "PaymentsForRepurchaseOfDebt", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "icpt_PayoutPercentageAsPercentOfTargetAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the payout percentage for awards, relative to TSR reference index.", "label": "Payout percentage, as percent of target award" } } }, "localname": "PayoutPercentageAsPercentOfTargetAward", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "icpt_PercentageOfCreditEligibleFromTaxAuthority": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of credit eligible from tax authority.", "label": "Percentage of credit eligible from tax authority", "terseLabel": "Percentage of credit eligible from tax authority" } } }, "localname": "PercentageOfCreditEligibleFromTaxAuthority", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "percentItemType" }, "icpt_PercentageOfPrincipalAmountOfConvertibleNotesIsEqualToRepurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of convertible notes is equal to repurchase price.", "label": "Percentage Of Principal Amount Of Convertible Notes Is Equal To Repurchase Price", "terseLabel": "Percentage of repurchase price is equal to principal amount of convertible notes" } } }, "localname": "PercentageOfPrincipalAmountOfConvertibleNotesIsEqualToRepurchasePrice", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "percentItemType" }, "icpt_PerformanceStockUnitsPsusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Performance stock units.", "label": "PRSUs" } } }, "localname": "PerformanceStockUnitsPsusMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "icpt_PrivatelyNegotiatedAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to privately negotiated agreements.", "label": "Privately negotiated agreements" } } }, "localname": "PrivatelyNegotiatedAgreementMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "domainItemType" }, "icpt_ResearchAndDevelopmentExpenditureCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Expenditure Credit [Member].", "label": "RDEC scheme" } } }, "localname": "ResearchAndDevelopmentExpenditureCreditMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "icpt_ResearchAndDevelopmentExpenseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and development expense, decrease.", "label": "Research And Development Expense Decrease", "terseLabel": "Research and development expense, decrease" } } }, "localname": "ResearchAndDevelopmentExpenseDecrease", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "icpt_ResearchAndDevelopmentExpenseDecreaseForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and development expense decrease foreign currency translation.", "label": "Research And Development Expense Decrease Foreign Currency Translation", "terseLabel": "Research and development expense decrease, foreign currency translation" } } }, "localname": "ResearchAndDevelopmentExpenseDecreaseForeignCurrencyTranslation", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "icpt_ResearchAndDevelopmentTaxCreditTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to the tax credit related to the entity's research and development.", "label": "Research and Development Tax Credit [Text Block]", "terseLabel": "Research and Development Tax Credit" } } }, "localname": "ResearchAndDevelopmentTaxCreditTextBlock", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCredit" ], "xbrltype": "textBlockItemType" }, "icpt_RestrictedAndPerformanceStockUnitsPsusAndAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to restricted and Performance stock units and awards.", "label": "RSUs, RSAs, and PRSUs" } } }, "localname": "RestrictedAndPerformanceStockUnitsPsusAndAwardsMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "domainItemType" }, "icpt_RestructuringCostsBenefits": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring cost (benefits).", "label": "Restructuring Costs Benefits", "terseLabel": "Restructuring" } } }, "localname": "RestructuringCostsBenefits", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "icpt_ScheduleOfInterestExpensesOnConvertibleNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expenses on convertible debt.", "label": "Schedule of Interest Expenses on Convertible Notes [Table Text Block]", "terseLabel": "Schedule of interest expenses on convertible debt" } } }, "localname": "ScheduleOfInterestExpensesOnConvertibleNotesTableTextBlock", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "icpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Performance Period", "terseLabel": "Performance period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "icpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsOnlyInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options expirations only in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations Only In Period", "negatedLabel": "Expired - Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsOnlyInPeriod", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "icpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsOnlyInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options expirations only in period weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations Only In Period Weighted Average Exercise Price", "terseLabel": "Expired - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsOnlyInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "icpt_SharePurchaseAgreementConsiderationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration receivable under the share purchase agreement.", "label": "Share Purchase Agreement, Consideration Receivable", "terseLabel": "Additional consideration receivable under SPA" } } }, "localname": "SharePurchaseAgreementConsiderationReceivable", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "icpt_SharesEquivalentOfBaseCappedCallOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares equivalent of base capped call options outstanding.", "label": "Shares Equivalent of Base Capped Call Options Outstanding", "terseLabel": "Base Capped Call options (in shares)" } } }, "localname": "SharesEquivalentOfBaseCappedCallOptionsOutstanding", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_SharesEquivalentOfCappedCallOptionsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares equivalent of capped call options terminated.", "label": "Shares Equivalent of Capped Call Options Terminated", "terseLabel": "Options terminated (in shares)" } } }, "localname": "SharesEquivalentOfCappedCallOptionsTerminated", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "icpt_SmallAndMediumSizedEnterpriseResearchAndDevelopmentTaxCreditSchemeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Small And Medium Sized Enterprise Research And Development Tax Credit Scheme [Member].", "label": "SME scheme" } } }, "localname": "SmallAndMediumSizedEnterpriseResearchAndDevelopmentTaxCreditSchemeMember", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "icpt_TaxCreditTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Credit Type [Axis].", "label": "Tax Credit Type [Axis]" } } }, "localname": "TaxCreditTypeAxis", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "icpt_TaxCreditTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Credit Type [Domain].", "label": "Tax Credit Type [Domain]" } } }, "localname": "TaxCreditTypeDomain", "nsuri": "http://www.interceptpharma.com/20220630", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r140", "r147", "r220", "r399", "r400", "r401", "r410", "r411", "r431", "r436", "r437", "r482" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r140", "r147", "r154", "r220", "r399", "r400", "r401", "r410", "r411", "r431", "r434", "r436", "r437", "r482" ], "lang": { "en-us": { "role": { "label": "Cumulative effect, period of adoption, adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r140", "r147", "r154", "r220", "r399", "r400", "r401", "r410", "r411", "r431", "r434", "r436", "r437", "r482" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r140", "r147", "r154", "r220", "r399", "r400", "r401", "r410", "r411", "r431", "r434", "r436", "r437", "r482" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r264", "r265", "r266", "r267", "r286", "r323", "r355", "r357", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r566", "r568", "r587", "r588" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r264", "r265", "r266", "r267", "r286", "r323", "r355", "r357", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r566", "r568", "r587", "r588" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r191", "r265", "r266", "r341", "r343", "r523", "r565", "r567" ], "lang": { "en-us": { "role": { "label": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r191", "r265", "r266", "r341", "r343", "r523", "r565", "r567" ], "lang": { "en-us": { "role": { "label": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r255", "r264", "r265", "r266", "r267", "r286", "r323", "r345", "r355", "r357", "r386", "r387", "r388", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r566", "r568", "r587", "r588" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r255", "r264", "r265", "r266", "r267", "r286", "r323", "r345", "r355", "r357", "r386", "r387", "r388", "r497", "r498", "r499", "r500", "r501", "r502", "r521", "r566", "r568", "r587", "r588" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policiies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r66" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Other Accrued Liabilities", "totalLabel": "Accounts payable, accrued expenses and other liabilities", "verboseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable, Accrued Expenses and Other Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r64", "r487" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of allowance for credit losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r194", "r195" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowance for credit losses of $51 and $58, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetailsAlternate": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of debt discount", "verboseLabel": "Accretion of debt discount" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "verboseLabel": "Accrued employee compensation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r49", "r528", "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued investment income receivable" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued rebates, returns, discounts and other incentives" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r247" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r80", "r81", "r82", "r553", "r576", "r580" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net Of Tax", "verboseLabel": "Accumulated other comprehensive loss, net" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r79", "r82", "r91", "r92", "r93", "r137", "r138", "r139", "r422", "r484", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss, Net" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r50", "r487" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r137", "r138", "r139", "r399", "r400", "r401", "r436" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r141", "r142", "r143", "r144", "r154", "r198", "r199", "r217", "r218", "r219", "r220", "r221", "r222", "r399", "r400", "r401", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r463", "r464", "r471", "r472", "r473", "r474", "r479", "r480", "r481", "r482", "r483", "r484", "r524", "r525", "r526", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Adjustments Related to Tax Withholding for Share-based Compensation", "negatedLabel": "Employee withholding taxes related to stock-based awards" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r359", "r403", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share based compensation expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Allocated Share-based Compensation Expense, Net of Tax", "terseLabel": "Allocated stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r56", "r196", "r223", "r225", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance at the end of period", "periodStartLabel": "Balance at the beginning of period", "terseLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetAllowanceForCreditLossesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Allowance for credit losses, Rollforward" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetAllowanceForCreditLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r103", "r124", "r306", "r468" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetailsAlternate": { "order": 3.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r43", "r133", "r180", "r183", "r189", "r216", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r418", "r423", "r445", "r485", "r487", "r529", "r551" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r36", "r63", "r133", "r216", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r418", "r423", "r445", "r485", "r487" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r440" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, fair value disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r6", "r7", "r24", "r26", "r30", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets of discontinued operations", "totalLabel": "Total assets classified as discontinued operations in condensed consolidated balance sheets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-For-Sale Securities, Gross Unrealized Gains", "terseLabel": "Total investments, Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-For-Sale Securities, Gross Unrealized Losses", "negatedLabel": "Total investments, Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r203", "r204", "r545" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available-For-Sale Securities, Debt Maturities, Next Twelve Months, Fair Value", "verboseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r33", "r136", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis Of Presentation [Text Block]", "verboseLabel": "Overview of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureOverviewOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "verboseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r39", "r126" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and cash equivalents, fair value disclosure", "verboseLabel": "Cash and cash equivalents, Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r121", "r126", "r129" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Cash, cash equivalents and restricted cash of continuing operations", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "auth_ref": [ "r121", "r126", "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "terseLabel": "Less: Cash, cash equivalents and restricted cash of discontinued operations" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r121", "r126", "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents and restricted cash included in the consolidated balance sheets:", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash included in the consolidated balance sheets:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r121", "r454" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash (used in) provided by financing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r23", "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash (used in) provided by investing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r23", "r121" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash provided by operating activities - discontinued operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r346", "r443" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r74", "r533", "r558" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r261", "r262", "r263", "r268", "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r137", "r138", "r436" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par Or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r48", "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r48", "r487" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock par value $0.001 per share; 90,000,000 shares authorized; 29,798,040 and 29,572,953 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r87", "r89", "r90", "r99", "r539", "r563" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Fair value of convertible debt" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r282", "r283", "r284", "r286", "r296", "r297", "r298", "r302", "r303", "r304", "r305", "r306", "r316", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible notes" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of initial conversion of convertible debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r346", "r353", "r581" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r105", "r133", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r445" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r104" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r127", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Convertible debt" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r127", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Convertible debt, original debt" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r131", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r300", "r307", "r308", "r310", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r44", "r45", "r46", "r132", "r135", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r316", "r317", "r318", "r319", "r469", "r530", "r531", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r46", "r312", "r531", "r550" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Equity component, net of issuance costs" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r285", "r314" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument, convertible, conversion price", "terseLabel": "Approximate conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r71", "r285", "r326", "r327", "r329" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt instrument, convertible, conversion ratio", "terseLabel": "Initial conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r283", "r316", "r317", "r467", "r469", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount", "terseLabel": "Debt, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r70", "r315", "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Liability Component Effective Interest Rate", "terseLabel": "Debt instrument liability component effective interest rate", "verboseLabel": "Interest rate, effective" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r70", "r284" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate, stated percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r72", "r132", "r135", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r316", "r317", "r318", "r319", "r469" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt instrument, redemption price, percentage", "terseLabel": "Average percentage of closing sale price of common stock" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Convertible debt repurchased" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Convertible debt repurchased, face amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r72", "r132", "r135", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r316", "r317", "r318", "r319", "r326", "r328", "r329", "r330", "r466", "r467", "r469", "r470", "r549" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtCappedCallTransactionsDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInitialConversionOfConvertibleDebtDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r296", "r466", "r470" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "terseLabel": "Convertible debt, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "negatedLabel": "Allowance for Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-For-Sale Securities, Amortized Cost Basis", "verboseLabel": "Total investments, Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r210", "r237", "r240" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Total available for sale securities, More than 12 months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r210", "r237" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss", "negatedLabel": "Total available for sale securities more than 12 months, Gross Unrealized Holding Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year", "terseLabel": "Number of positions that were in a continuous unrealized loss position for more than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r210", "r237", "r240" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-For-Sale Securities, Continuous Unrealized Loss Position, Less Than Twelve Months, Fair Value", "verboseLabel": "Total available for sale securities, Less than 12 months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r210", "r237" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-For-Sale Securities, Continuous Unrealized Loss Position, Less Than 12 Months, Aggregate Losses", "negatedLabel": "Total available for sale securities Less than 12 months, Gross Unrealized Holding Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "auth_ref": [ "r232" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale securities, fair value disclosure", "totalLabel": "Total investment debt securities", "verboseLabel": "Total investments, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsScheduleOfAvailableForSaleSecuritiesDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "auth_ref": [ "r232" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available-For-Sale Securities, Current", "terseLabel": "Investment debt securities, available-for-sale" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of Available for Sale Securities Debt Maturities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r208", "r233", "r240" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value", "totalLabel": "Available-for-sale securities, Total Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r209", "r234" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss", "negatedTotalLabel": "Available-for-sale securities, Total Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r207", "r236", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsCurrentGross": { "auth_ref": [ "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Related Commitment Fees and Debt Issuance Costs" } } }, "localname": "DeferredFinanceCostsCurrentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r296", "r468" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs", "verboseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtExchangeOfConvertibleDebtNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r124", "r245" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r361", "r362", "r392", "r393", "r396", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]", "terseLabel": "Stock Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Net income from discontinued operations, Basic (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Net income from discontinued operations, Diluted (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r8", "r9", "r26" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Held-for-sale", "terseLabel": "Held for sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r15", "r31" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Held for Sale and Discontinued Operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r6", "r7", "r24", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net of allowance for credit losses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r6", "r7", "r24", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r22", "r30" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Long-term other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "auth_ref": [ "r6", "r7", "r24", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Fixed assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r22", "r30" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Product revenue, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r32", "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r100", "r145", "r146", "r147", "r148", "r149", "r155", "r157", "r159", "r160", "r161", "r165", "r166", "r437", "r438", "r540", "r564" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss, Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r100", "r145", "r146", "r147", "r148", "r149", "r157", "r159", "r160", "r161", "r165", "r166", "r437", "r438", "r540", "r564" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss, Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r162", "r163", "r164", "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r454" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash and Cash Equivalents", "verboseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition", "verboseLabel": "Share-based compensation not yet recognized, period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Share-Based Awards Other Than Options", "verboseLabel": "Share-based compensation not yet recognized, other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options", "verboseLabel": "Share-based compensation not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r91", "r92", "r93", "r137", "r138", "r139", "r142", "r150", "r153", "r168", "r220", "r325", "r331", "r399", "r400", "r401", "r410", "r411", "r436", "r455", "r456", "r457", "r458", "r459", "r461", "r484", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "verboseLabel": "Fair Value, Marketable Securities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r440", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r298", "r316", "r317", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r441", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r298", "r346", "r347", "r352", "r353", "r441", "r494" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r298", "r316", "r317", "r346", "r347", "r352", "r353", "r441", "r495" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r298", "r316", "r317", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r441", "r496" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r298", "r316", "r317", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtFairValueOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r205", "r206", "r213", "r214", "r215", "r224", "r228", "r229", "r230", "r231", "r236", "r238", "r239", "r240", "r309", "r324", "r427", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r595", "r596", "r597", "r598", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign tax authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r475" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain on lease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r124", "r320", "r321" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_HerMajestysRevenueAndCustomsHMRCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of United Kingdom.", "label": "UK tax authority" } } }, "localname": "HerMajestysRevenueAndCustomsHMRCMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r124", "r243", "r249" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Write-off of fixed assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r133", "r141", "r180", "r182", "r185", "r188", "r190", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r417", "r438", "r445" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r95", "r100", "r141", "r145", "r146", "r147", "r148", "r157", "r159", "r160", "r438", "r534", "r536", "r540", "r559" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss from continuing operations, Basic (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r95", "r100", "r141", "r145", "r146", "r147", "r148", "r157", "r159", "r160", "r161", "r438", "r540", "r559", "r562", "r564" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Net loss from continuing operations, Diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r10", "r11", "r12", "r13", "r14", "r27", "r30", "r412", "r560" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails": { "order": 7.0, "parentTag": "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "weight": -1.0 }, "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income from discontinued operations", "totalLabel": "Income from discontinued operations in condensed consolidated statements of operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r10", "r11", "r12", "r13", "r14", "r21", "r27", "r417" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from discontinued operations", "verboseLabel": "Less: Net income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Discontinued Operations" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r7", "r15", "r16", "r17", "r18", "r19", "r20", "r25", "r28", "r29", "r30", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNarrativesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsNetCashProvidedByOperatingActivitiesDetails", "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsResultsOfOperationsDetails", "http://www.interceptpharma.com/role/DisclosureOverviewOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r250", "r258" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) In Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable, accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositsOutstanding": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Increase (Decrease) in Deposits Outstanding", "negatedLabel": "Security deposits" } } }, "localname": "IncreaseDecreaseInDepositsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) In Interest Payable, Net", "terseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r123", "r476" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) In Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest and Dividends Payable, Current", "terseLabel": "Short-term interest payable" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r96", "r179", "r465", "r468", "r542" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetailsAlternate": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "negatedLabel": "Interest expense", "totalLabel": "Total interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseLongTermDebt": { "auth_ref": [ "r541", "r595", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest paid or due on all long-term debt.", "label": "Interest Expense, Long-term Debt", "terseLabel": "Cash payments for interest" } } }, "localname": "InterestExpenseLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expense, Long-term Debt [Abstract]" } } }, "localname": "InterestExpenseLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable, current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r35", "r62", "r487" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventory" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r58" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r109" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income, Amortization Of Premium", "verboseLabel": "Amortization of premium on investment debt securities" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Investment Debt Securities" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r212", "r527", "r546", "r582", "r602" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt and Marketable Equity Securities (And Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Cash, Cash Equivalents and Investment Debt Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r67", "r133", "r184", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r419", "r423", "r424", "r445", "r485", "r486" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r55", "r133", "r216", "r445", "r487", "r532", "r555" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r69", "r133", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r419", "r423", "r424", "r445", "r485", "r486", "r487" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r6", "r7", "r24", "r26", "r30", "r244", "r251" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Total liabilities classified as discontinued operations in condensed consolidated balance sheets" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r46", "r297", "r313", "r316", "r317", "r531", "r552" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "totalLabel": "Long-term Debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-term Debt, Excluding Current Maturities", "netLabel": "Convertible Notes", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt outstanding" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r72", "r270" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtNoteIndenturesDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal bonds" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By (Used In) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By (Used In) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities - continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By (Used In) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By (Used In) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r121" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash (used in) provided by investing activities - continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r121", "r122", "r125" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By (Used In) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By (Used In) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r121", "r122", "r125" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities - continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r30", "r85", "r88", "r93", "r97", "r125", "r133", "r141", "r145", "r146", "r147", "r148", "r152", "r153", "r158", "r180", "r182", "r185", "r188", "r190", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r438", "r445", "r537", "r561" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable To Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities", "verboseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense), Total", "totalLabel": "Total other (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office equipment and software" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r180", "r182", "r185", "r188", "r190" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r106", "r124" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Net changes related to available-for-sale investment debt securities:" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r77", "r78" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax", "terseLabel": "Unrealized losses on investment debt securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r77", "r78", "r80" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax", "totalLabel": "Net unrealized losses on investment debt securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r76" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation gains (losses)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r86", "r89", "r91", "r92", "r94", "r98", "r325", "r455", "r460", "r461", "r538", "r562" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net Of Tax", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r80", "r83", "r84", "r211" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Reclassification adjustment for realized losses on investment debt securities included in other income, net" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense)", "verboseLabel": "Other (expense) income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r73" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Long-term other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Expenses and Other Liabilities" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r119" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payments of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r118" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related to Tax Withholding for Share-based Compensation", "negatedLabel": "Payments of employee withholding taxes related to stock-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r111", "r114", "r200" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments To Acquire Available-For-Sale Securities", "negatedLabel": "Purchases of investment debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r115" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of equipment, leasehold improvements, and furniture and fixtures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r117" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible debt", "terseLabel": "Proceeds from issuance of Convertible Notes, net of issuance costs", "verboseLabel": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r111", "r112", "r200" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale Of Available-For-Sale Securities", "verboseLabel": "Sales and maturities of investment debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Cash consideration received" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r116", "r398" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "verboseLabel": "Proceeds from exercise of options, net" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r30", "r85", "r88", "r93", "r120", "r133", "r141", "r152", "r153", "r180", "r182", "r185", "r188", "r190", "r216", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r417", "r420", "r421", "r425", "r426", "r438", "r445", "r543" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fixed Assets, Net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r254", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Fixed Assets, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "verboseLabel": "Property, Plant and Equipment, Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r246" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Fixed assets" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r248", "r487", "r547", "r557" ], "calculation": { "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Fixed assets, net", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Fixed Assets, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life", "verboseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails", "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r101", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "negatedLabel": "Provision for credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetAllowanceForCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForOtherCreditLosses": { "auth_ref": [ "r123", "r535" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions.", "label": "Provision for Other Credit Losses", "terseLabel": "Provision for allowance of credit losses, net of write-offs" } } }, "localname": "ProvisionForOtherCreditLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Tax Credit" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r406", "r522", "r589" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r39", "r129" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted stock units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r331", "r487", "r554", "r575", "r580" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Development Stage Enterprise, Deficit Accumulated During Development Stage", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r137", "r138", "r139", "r142", "r150", "r153", "r220", "r399", "r400", "r401", "r410", "r411", "r436", "r571", "r573" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Revenue, Net" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r177", "r178", "r181", "r186", "r187", "r191", "r192", "r193", "r340", "r341", "r523" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Product revenue, net", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r342", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Product Revenue Net [Text Block]", "terseLabel": "Product Revenue, Net" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureProductRevenueNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r477", "r478" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "negatedTerseLabel": "Right-of-use asset obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of fair value of the convertible notes" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Cash, Cash Equivalents and Investment Debt Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule Of Stock Based Compensation Expense [Table Text Block]", "verboseLabel": "Schedule of Stock Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r72", "r135", "r316", "r318", "r326", "r328", "r329", "r330", "r466", "r467", "r470", "r549" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r7", "r15", "r16", "r17", "r18", "r19", "r20", "r25", "r28", "r29", "r30", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureDiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r390", "r402" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule of adjustments made condensed consolidated balance sheet on adopting ASU 2020-06" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r38", "r59", "r60", "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]", "terseLabel": "Schedule of Share Based Compensation Stock Options Activities" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r358", "r360", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share-Based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "verboseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share Based Compensation Arrangement By Share Based Payment Award Grants in Period Fair Value Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesAssetsMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "A share, participation, or other interest in property or in an enterprise of the issuer or an obligation of the issuer that (a) either is represented by an instrument issued in bearer or registered form or, if not represented by an instrument, is registered in books maintained to record transfers by or on behalf of the issuer, (b) is of a type commonly dealt in on securities exchanges or markets or, when represented by an instrument, is commonly recognized in any area in which it is issued or dealt in as a medium for investment, and (c) either is one of a class or series or by its terms is divisible into a class or series of shares, participations, interest, or obligations.", "label": "Securities (Assets) [Member]" } } }, "localname": "SecuritiesAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r42" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit", "verboseLabel": "Security deposits" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r107" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r123" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited - Shares", "verboseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited - Weighted Average Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period", "verboseLabel": "Granted - Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted - Weighted Average Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number", "periodEndLabel": "Outstanding, at ending period", "periodStartLabel": "Outstanding, at beginning period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding - Weighted Average Fair Value, at ending period", "periodStartLabel": "Outstanding - Weighted Average Fair Value, at beginning period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period", "negatedLabel": "Vested - Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested - Weighted Average Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable - Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period", "negatedLabel": "Cancelled/forfeited - Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period, Weighted Average Exercise Price", "verboseLabel": "Cancelled/forfeited - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross", "verboseLabel": "Granted - Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Options Outstanding - Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Outstanding, Number of Shares", "periodStartLabel": "Beginning Outstanding, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Outstanding, Weighted Average Exercise Price", "periodStartLabel": "Beginning Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Expected to vest - Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Expected to vest - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Expected to vest - Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationRestrictedStockUnitsAndAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price", "verboseLabel": "Exercised - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price", "verboseLabel": "Granted - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Share based payment award, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Exercisable - Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Exercisable - Weighted Average Remaining Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Options Outstanding - Weighted Average Remaining Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Expected to vest - Weighted Average Remaining Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share", "verboseLabel": "Issue price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Employee withholding taxes related to stock-based awards, (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r130", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r75", "r91", "r92", "r93", "r137", "r138", "r139", "r142", "r150", "r153", "r168", "r220", "r325", "r331", "r399", "r400", "r401", "r410", "r411", "r436", "r455", "r456", "r457", "r458", "r459", "r461", "r484", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Stockholders' (Deficit)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r137", "r138", "r139", "r168", "r523" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureAccountsPayableAccruedExpensesAndOtherLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureFixedAssetsNetFixedAssetsStatedAtCostDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsAndInterestExpenseDetails", "http://www.interceptpharma.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.interceptpharma.com/role/DisclosureProductRevenueNetNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureResearchAndDevelopmentTaxCreditNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails", "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r47", "r48", "r325", "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Shares granted during period for stock based compensation" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services, (in shares)", "verboseLabel": "Issuance of common stock for services related to exchange of convertible notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock issued during period, shares, share-based compensation, gross", "verboseLabel": "Issuance of common stock under equity plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r47", "r48", "r325", "r331", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period", "negatedLabel": "Exercised - Number of Shares", "verboseLabel": "Net proceeds from exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationScheduleOfShareBasedCompensationStockOptionsActivitiesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued for services", "verboseLabel": "Issuance of common stock for services related to exchange of convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Issuance of common stock under equity plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r75", "r325", "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Net proceeds from exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureStockCompensationNarrativeDetails", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r48", "r53", "r54", "r133", "r197", "r216", "r445", "r487" ], "calculation": { "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable To Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Abstract]", "verboseLabel": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r462", "r489" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event." } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r462", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r462", "r489" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r488", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash transactions:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r205", "r206", "r213", "r214", "r215", "r309", "r324", "r427", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r595", "r596", "r597", "r598", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Major Types Of Debt and Equity Securities [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r141", "r142", "r143", "r144", "r154", "r198", "r199", "r217", "r218", "r219", "r220", "r221", "r222", "r399", "r400", "r401", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r463", "r464", "r471", "r472", "r473", "r474", "r479", "r480", "r481", "r482", "r483", "r484", "r524", "r525", "r526", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureLongTermDebtNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r134", "r346", "r544" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U.S. government agency bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r134", "r346", "r353", "r544" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U.S Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesAvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueDetails", "http://www.interceptpharma.com/role/DisclosureCashCashEquivalentsAndInvestmentDebtSecuritiesCashCashEquivalentsAndInvestmentDebtSecuritiesDetails", "http://www.interceptpharma.com/role/DisclosureFairValueMeasurementsFairValueMarketableSecuritiesMeasuredOnRecurringAndNonrecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r169", "r170", "r171", "r172", "r173", "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r156", "r161" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r155", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted average common and potential common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.interceptpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r32": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r33": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r527": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r546": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r582": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r591": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r592": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r593": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r594": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r595": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r596": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r597": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r598": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r599": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r601": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r602": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r603": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" } }, "version": "2.1" }